Abstract 927
Background
This prospective study is to determine whether predictive model for contrast-enhanced ultrasound (CEUS) of the breast can improve the precision of BI-RADS.
Methods
A total of 1060 breast lesions classified as BI-RADS 4 or 5 on ultrasound were evaluated. CEUS was performed before core needle biopsy or surgical resection and a revised BI-RADS classification was assigned based on 6 predictive models for CEUS of malignant and benign breast lesions as follows: malignant predictive models : (1) hyper-enhancement with enlarged size; (2) hyper-enhancement with perfusion defect; (3) hyper- or iso-enhancement, present penetrating vessels or crab claw-like pattern. Benign predictive models: (4) rapid wash-in with hyper-enhancement, clear margin after enhancement without enlarged size; (5) synchronous or slow wash-in with iso-enhancement, and cannot distinguish margin and shape after enhancement; and (6) synchronous or slow wash-in with hypo-enhancement, with equal or smaller size after enhancement. To evaluate the diagnostic performance of CEUS-based BI-RADS assignment with pathological examination as reference criteria.
Results
The CEUS-based BI-RADS evaluation classified 287/1060 (27.08%) lesions into category 3, 195 (18.40%), 124 (11.7%) and 144 (13.58%) lesions into categories 4A, 4B and 4C, respectively, and 310 (29.24%) into category 5, compared with 423/1060(39.91%), 348(32.83%), 150(14.15%) and 139(13.11%) in BI-RADS 4A, 4B, 4C. and 5 based on conventional ultrasound and mammography. Selecting CEUS- based BI-RADS category 3 as an appropriate cut-off gave accuracy, sensitivity, specificity, positive and negative predictive values of 69.25%, 98.06%, 49.47%, 58.99% and 96.86%, respectively for the diagnosis of malignant disease. The cancer-to-biopsy yield was 60.16% with CEUS-based BI-RADS 3 selected as the biopsy threshold compared with 43.86% otherwise, while the biopsy rate was only 72.92% compared with 100% otherwise (Figure 2). Overall, only 1.94% of invasive cancers were misdiagnosed as BI-RADS 3 we use nowadays.
Conclusions
This study suggests that evaluation of BI-RADS 4 or 5 breast lesions with CEUS result in reduced biopsy rates and increased cancer-to-biopsy yields.
Clinical trial identification
2016-14-1 release date: 9/9/2016.
Legal entity responsible for the study
Ultrasound Department of Sichuan Provincial People's Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4679 - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Presenter: Chung-Han Lee
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5379 - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
Presenter: Armin Meier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5394 - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System
Presenter: Ankur Parikh
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5884 - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies
Presenter: Yali Li
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5912 - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.
Presenter: Blanca Torrejón
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1168 - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs
Presenter: Nasha Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3071 - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
Presenter: Muhammad Khattak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4062 - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
Presenter: Yu-Zhen Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4801 - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study
Presenter: Tian Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4874 - Dissecting Gastric Cancer biology and how and when to use immunotherapy
Presenter: Meghna Das Thakur
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract